# About Tesa Source: An Editorial Digest of the Tesamorelin Literature

> Tesa Source is an independent editorial project summarizing the peer-reviewed research on tesamorelin. Not a clinic, not a vendor; editorial commentary on publicly available science.

An independent editorial reading room for the published tesamorelin research — one lamp on the manuscript, nothing on a shelf.

## What Tesa Source is

Tesa Source is an independent editorial project that publishes summaries of the peer-reviewed research literature on tesamorelin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site reads the tesamorelin record through one deliberate lens — pharmacokinetics — because the compound's most instructive feature is the gap between how briefly it stays in the plasma and how long its IGF-1 signal lasts. That single contrast organizes the digest, from the half-life page to the mechanism summary to the structural comparison with sermorelin.

## What the name means

"Source" here is bibliographic, not commercial. It refers to the studies a claim is sourced to — the candlelit study where one lamp falls on the open page — never to a supplier of the compound. Nothing on this site is for sale, listed, or priced, and no part of it directs a reader to obtain tesamorelin. The negative-space restraint is intentional: this is a literature reading, not a storefront.

Where a page describes research-grade tesamorelin, it describes the material as it appears in laboratory research — which is not the finished drug product and not a medicine to self-administer. The approved product is a prescription drug for a specific HIV indication; this digest does not blur that line.

## How we handle the evidence

Every quantitative statement here is attributed to a numbered source on the references page, and we keep the provenance of secondary figures explicit — the ~26-38 minute terminal half-life, for instance, is attributed to the FDA label and clinical references rather than to the population-PK analysis, which reports clearance and absorption instead. We describe what was administered, to which population, by which route, and at which dose, and we do not translate any of it into guidance.

We also keep the approval scope precise: tesamorelin is FDA-approved solely to reduce excess abdominal fat in HIV-associated lipodystrophy, and every other use is off-label. The aim is a reading you can trust on the details — the figures, the populations, and the boundaries of what the studies actually showed.

---

One lamp on the tesamorelin record — the minutes-long plasma clearance and the day-long IGF-1 afterglow read straight from the studies and cited to source, with no clinic behind the candle and nothing here dispensed, priced, or sold.